{"id":"guselkumab-dose-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2364648","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Guselkumab binds to the p19 subunit of IL-23, a key cytokine involved in the differentiation and activation of pathogenic T helper 17 (Th17) cells. By inhibiting IL-23 signaling, the drug suppresses the inflammatory cascade underlying psoriasis and other immune-mediated conditions. This targeted approach reduces systemic inflammation while preserving other immune functions.","oneSentence":"Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:43.597Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT05242484","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-19","conditions":"Colitis, Ulcerative","enrollment":577},{"nctId":"NCT03466411","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-13","conditions":"Crohn's Disease","enrollment":1409},{"nctId":"NCT05528510","phase":"PHASE3","title":"A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-13","conditions":"Colitis, Ulcerative","enrollment":418},{"nctId":"NCT05083182","phase":"PHASE3","title":"A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-30","conditions":"Arthritis, Juvenile","enrollment":50},{"nctId":"NCT06260163","phase":"PHASE3","title":"A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-01-19","conditions":"Colitis, Ulcerative","enrollment":112},{"nctId":"NCT04882098","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Active Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-06-17","conditions":"Arthritis, Psoriatic","enrollment":1054},{"nctId":"NCT07102368","phase":"","title":"A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany","status":"RECRUITING","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2025-08-18","conditions":"Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease","enrollment":400},{"nctId":"NCT05347095","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen-Cilag Ltd.","startDate":"2022-09-27","conditions":"Fistulizing Crohns Disease, Perianal Crohns Disease","enrollment":288},{"nctId":"NCT06663332","phase":"PHASE3","title":"A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-29","conditions":"Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic","enrollment":196},{"nctId":"NCT03451851","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-11","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT04033445","phase":"PHASE2, PHASE3","title":"A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-26","conditions":"Ulcerative Colitis","enrollment":1064},{"nctId":"NCT06398106","phase":"PHASE4","title":"Proactive TDM Versus Standard Use of Biologics in Psoriasis","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2024-12-20","conditions":"Psoriasis Vulgaris","enrollment":210},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT06249555","phase":"","title":"VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study","status":"RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2024-03-20","conditions":"Crohn's Disease","enrollment":300},{"nctId":"NCT05197049","phase":"PHASE3","title":"A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-01-19","conditions":"Crohn Disease","enrollment":350},{"nctId":"NCT05923073","phase":"PHASE3","title":"A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-03-13","conditions":"Crohn's Disease","enrollment":120},{"nctId":"NCT05242471","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-22","conditions":"Crohn's Disease","enrollment":703},{"nctId":"NCT05535738","phase":"PHASE2, PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":"Skin Inflammation, Allergic Contact Dermatitis","enrollment":45},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04683029","phase":"PHASE2","title":"A Study of Guselkumab in Participants With Systemic Sclerosis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-02-24","conditions":"Scleroderma, Systemic","enrollment":56},{"nctId":"NCT05004727","phase":"PHASE4","title":"Multi-Center PAMPA Study","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-02-16","conditions":"Psoriasis","enrollment":176},{"nctId":"NCT05784129","phase":"PHASE3","title":"A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-02-21","conditions":"Crohn's Disease","enrollment":4},{"nctId":"NCT04376827","phase":"PHASE2","title":"A Study of Guselkumab in Participants With Active Lupus Nephritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-15","conditions":"Lupus Nephritis","enrollment":33},{"nctId":"NCT03628924","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-04","conditions":"Hidradenitis Suppurativa","enrollment":184},{"nctId":"NCT04030533","phase":"PHASE1","title":"Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-29","conditions":"Healthy","enrollment":60},{"nctId":"NCT03649971","phase":"PHASE1","title":"A Study of Guselkumab in Participants With Familial Adenomatous Polyposis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-19","conditions":"Adenomatous Polyposis Coli","enrollment":77},{"nctId":"NCT02570373","phase":"PHASE1","title":"A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-25","conditions":"Healthy","enrollment":8},{"nctId":"NCT03662542","phase":"PHASE2","title":"A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-20","conditions":"Colitis, Ulcerative","enrollment":214},{"nctId":"NCT04261010","phase":"NA","title":"TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-01-14","conditions":"Psoriatic Arthritis","enrollment":36},{"nctId":"NCT05083078","phase":"PHASE1","title":"A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-04","conditions":"Arthritis, Psoriatic, Healthy","enrollment":11},{"nctId":"NCT03573323","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-09","conditions":"Plaque Psoriasis","enrollment":1027},{"nctId":"NCT02951533","phase":"PHASE3","title":"A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2016-12-12","conditions":"Psoriasis","enrollment":119},{"nctId":"NCT03536325","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2018-05-31","conditions":"Healthy","enrollment":24},{"nctId":"NCT02397382","phase":"PHASE1","title":"Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-06-18","conditions":"Psoriasis","enrollment":16},{"nctId":"NCT01483599","phase":"PHASE2","title":"A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-11-10","conditions":"Psoriasis","enrollment":293},{"nctId":"NCT01645280","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08","conditions":"Arthritis, Rheumatoid","enrollment":274}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CNTO 1959","CNTO1959"],"phase":"phase_3","status":"active","brandName":"Guselkumab Dose 1","genericName":"Guselkumab Dose 1","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}